Acorda Therapeutics Provides 2012 Corporate Update at 30th Annual J.P. Morgan Healthcare Conference

HAWTHORNE, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that AMPYRA® (dalfampridine) Extended Release Tablets, 10 mg unaudited net sales for the fourth quarter of 2011 were $57 million and unaudited AMPYRA 2011 full year net sales were $210 million. These results are subject to completion of the Company’s year-end audit.

MORE ON THIS TOPIC